Search research articles
Contact Us
Filters
Showing results (241-250 of 265) with videos related to
Page
of 27
Sort By:
JCO Precision Oncology
|
April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
JCO Precision Oncology
|
November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
Daniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2023
The New NCI Precision Medicine Trials
Lyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Diana M Merino, Lisa M McShane, David Fabrizio, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 26, 2018
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer
David L Rimm, Samuel C Y Leung, Lisa M McShane, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 265) with videos related to
Sort By:
Page
of 27
JCO Precision Oncology
|
April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
JCO Precision Oncology
|
November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
Daniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Niamh Coleman, Zihan Wei, A John Iafrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2023
The New NCI Precision Medicine Trials
Lyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
Journal for Immunotherapy of Cancer
|
March 29, 2020
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Diana M Merino, Lisa M McShane, David Fabrizio, et al.
JCO Precision Oncology
|
February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 26, 2018
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer
David L Rimm, Samuel C Y Leung, Lisa M McShane, et al.
Page
of 27